Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
Inventiva S.A. - American Depository Shares (IVA)
Company Research
Source: GlobeNewswire
Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced the completion of patient enrollment in its NATiV3 Phase 3 clinical trial with the randomization of the last patient in the main cohort. Inventiva has enrolled 1009 patients in the main cohort and 410 patients in the exploratory cohort exceeding the original target of 969 and 350, respectively. Frederic Cren, CEO and cofounder
Show less
Read more
Impact Snapshot
Event Time:
IVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IVA alerts
High impacting Inventiva S.A. - American Depository Shares news events
Weekly update
A roundup of the hottest topics
IVA
News
- Inventiva to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025GlobeNewswire
- Inventiva reports 2025 Third Quarter Financial Information¹GlobeNewswire
- Inventiva (NASDAQ:IVA) had its price target lowered by analysts at Guggenheim from $13.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5MGlobeNewswire
IVA
Earnings
- 9/29/25 - Miss
IVA
Sec Filings
- 11/28/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/19/25 - Form SCHEDULE
- IVA's page on the SEC website